Firefly luciferase-based chronological measurement of effector CD8+ T-cell activity using a multi-chamber luminometer

被引:1
|
作者
Hayashi, Ryota [1 ]
Nakatani, Hayato [2 ]
Kawahata, Hinami [2 ]
Fujie, Ryonosuke [1 ]
Kurowarabe, Kaoru [1 ]
Hayasaka, Haruko [1 ,2 ,3 ]
机构
[1] 1Kindai Univ, Grad Sch Sci & Engn, Dept Sci, Higashiosaka, Osaka 5778502, Japan
[2] 2Kindai Univ, Fac Sci & Engn, Higashiosaka, Osaka 5778502, Japan
[3] Kindai Univ, Inst Sci & Technol 3Research, Higashiosaka, Osaka 5778502, Japan
关键词
bioluminescence; CD8(+) T cell; luciferase; melanoma; IMMUNITY; IDENTIFICATION; IMMUNOTHERAPY; CYTOTOXICITY; VACCINE; ASSAY;
D O I
10.4155/bio-2022-0208
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Although cell-mediated cytotoxicity has been evaluated with various protocols, methods for monitoring cytotoxicity in a time series have not been established. This work describes a method for evaluating cytotoxicity using a multi-chamber real-time luminometer. Materials & methods: The efficiency of effector CD8(+) T-cell expansion from melanoma-bearing splenocytes was analyzed. The effect of CD8(+) T cells on the viability of luciferase-expressing target cells was measured by bioluminescence. Results: Melanoma-specific effector CD8(+) T cells were differentiated by in vitro coculture. The melanoma cell growth was significantly inhibited in the presence of in vitro-expanded T cells in the bioluminescence-based time-lapse analysis. Conclusion: The bioluminescence-based assay is a useful method for monitoring the time course of cell viability of target tumor cells.
引用
收藏
页码:1413 / 1421
页数:9
相关论文
共 50 条
  • [21] Site-specific antigen-adjuvant conjugation using cell-free protein synthesis enhances antigen presentation and CD8+ T-cell response
    Weiss, Adam M.
    Ajit, Jainu
    Albin, Tyler J.
    Kapoor, Neeraj
    Maroju, Shilpa
    Berges, Aym
    Pill, Lucy
    Fairman, Jeff
    Esser-Kahn, Aaron P.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [22] Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+ T-cell functionality
    Niavarani, Seyedeh-Raheleh
    Lawson, Christine
    Boudaud, Marie
    Simard, Camille
    Tai, Lee-Hwa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [23] Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients
    Goldinger, Simone M.
    Dummer, Reinhard
    Baumgaertner, Petra
    Mihic-Probst, Daniela
    Schwarz, Katrin
    Hammann-Haenni, Anya
    Willers, Joerg
    Geldhof, Christine
    Prior, John O.
    Kuendig, Thomas M.
    Michielin, Olivier
    Bachmann, Martin F.
    Speiser, Daniel E.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (11) : 3049 - 3061
  • [24] Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8+ T-cell responses and reduce the immunosuppressive activity of MDSCs
    Xu, Xiaojing
    Jin, Ziqi
    Liu, Yonghao
    Gong, Huanle
    Sun, Qing
    Zhang, Weidong
    Zhao, Lixiang
    CANCER LETTERS, 2019, 440 : 94 - 105
  • [25] The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses
    Chua, Brendon Y.
    Olson, Matthew R.
    Bedoui, Sammy
    Sekiya, Toshiki
    Wong, Chinn Y.
    Turner, Stephen J.
    Jackson, David C.
    IMMUNOLOGY AND CELL BIOLOGY, 2014, 92 (04) : 377 - 383
  • [26] Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells
    Bleakley, Marie
    Otterud, Brith E.
    Richardt, Julia L.
    Mollerup, Audrey D.
    Hudecek, Michael
    Nishida, Tetsuya
    Chaney, Colette N.
    Warren, Edus H.
    Leppert, Mark F.
    Riddell, Stanley R.
    BLOOD, 2010, 115 (23) : 4923 - 4933
  • [27] Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD8+ T-cell differentiation
    McQueen, Bryan
    Trace, Kelsey
    Whitman, Emily
    Bedsworth, Taylor
    Barber, Amorette
    IMMUNOLOGY, 2016, 147 (03) : 305 - 320
  • [28] Visualizing CTL activity for different CD8+ effector T cells supports the idea that lower TCR/epitope avidity may be advantageous for target cell killing
    M R Jenkins
    N L La Gruta
    P C Doherty
    J A Trapani
    S J Turner
    N J Waterhouse
    Cell Death & Differentiation, 2009, 16 : 537 - 542
  • [29] Visualizing CTL activity for different CD8+ effector T cells supports the idea that lower TCR/epitope avidity may be advantageous for target cell killing
    Jenkins, M. R.
    La Gruta, N. L.
    Doherty, P. C.
    Trapani, J. A.
    Turner, S. J.
    Waterhouse, N. J.
    CELL DEATH AND DIFFERENTIATION, 2009, 16 (04) : 537 - 542
  • [30] TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8+ T cell function
    Wang, Ran
    Xu, Jiefang
    Cheng, Shipeng
    Ling, Zhiyang
    Sonam, Wangmo
    Yang, Jichao
    Jin, Fuquan
    Wen, Jing
    Lu, Xiao
    Ma, Liyan
    Zhang, Yaguang
    Sun, Xiaoyu
    Yi, Chunyan
    Sun, Bing
    ONCOIMMUNOLOGY, 2025, 14 (01):